Floatz logo

Midostaurin

Myelodysplastic Syndrome/Acute Myeloid Leukemia

National Cancer Institute (NCI)Small moleculePhase 2/3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Myelodysplastic Syndrome/Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Azacitidine
City of Hope Medical Center
Phase 2/3BB
Decitabine
National Cancer Institute (NCI)
Phase 2/3B
Nivolumab
National Cancer Institute (NCI)
Phase 2/3B
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2/3B
Irinotecan
National Cancer Institute (NCI)
Phase 2CCC

View all 21 →

Same molecule, other indications

Midostaurin is also rated in:

acute myeloid leukemia by FAB classificationDormant
B
Indicative ·
63 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →